Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
暂无分享,去创建一个
C. Wells | R. Chan | Zhon-Yin Zhang | R. Mali | R. Kapur | A. Gunawan | Lifan Zeng | Li Wu | Ruo-yu Zhang | X. Li | Zhi-hong Yu | Brandon S. Lane | Sijiu Li
[1] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2014, Cell.
[2] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[3] J. Turchi,et al. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. , 2013, Biochemical and biophysical research communications.
[4] M. Loh,et al. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). , 2013, Journal of medicinal chemistry.
[5] Alexander D. MacKerell,et al. Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies , 2013, Molecular Cancer Therapeutics.
[6] Nunzio Bottini,et al. A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. , 2013, Journal of medicinal chemistry.
[7] Jie Xu,et al. A Facile Hydroxyindole Carboxylic Acid Based Focused Library Approach for Potent and Selective Inhibitors of Mycobacterium Protein Tyrosine Phosphatase B , 2013, ChemMedChem.
[8] Jie Xu,et al. Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold. , 2013, Journal of medicinal chemistry.
[9] Dario R Alessi,et al. Kinase drug discovery--what's next in the field? , 2013, ACS chemical biology.
[10] Zhon-Yin Zhang,et al. Small molecule tools for functional interrogation of protein tyrosine phosphatases , 2013, The FEBS journal.
[11] S. Muthuswamy,et al. Cell polarity as a regulator of cancer cell behavior plasticity. , 2012, Annual review of cell and developmental biology.
[12] G. Sandusky,et al. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. , 2012, Blood.
[13] Stephen J. Elledge,et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop , 2012, Nature Medicine.
[14] Zhong-xian Lu,et al. Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. , 2011, Bioorganic & medicinal chemistry letters.
[15] Zhon-Yin Zhang,et al. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening. , 2011, Bioorganic & medicinal chemistry letters.
[16] B. Shen,et al. SHP2 is a target of the immunosuppressant tautomycetin. , 2011, Chemistry & biology.
[17] W. Guida,et al. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. , 2011, Bioorganic & medicinal chemistry letters.
[18] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[19] R. Chan,et al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). , 2010, Journal of medicinal chemistry.
[20] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[21] Yuehong Wang,et al. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents , 2010, Proceedings of the National Academy of Sciences.
[22] W. Birchmeier,et al. The tyrosine phosphatase Shp2 in development and cancer. , 2010, Advances in cancer research.
[23] S. Hardy,et al. Inside the human cancer tyrosine phosphatome , 2010, Nature Reviews Cancer.
[24] Joe W. Gray,et al. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment , 2010, Breast Cancer Research and Treatment.
[25] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[26] T. Hunter. Tyrosine phosphorylation: thirty years and counting. , 2009, Current opinion in cell biology.
[27] T. Mustelin,et al. A Conserved Mechanism for Control of Human and Mouse Embryonic Stem Cell Pluripotency and Differentiation by Shp2 Tyrosine Phosphatase , 2009, PloS one.
[28] Wen Hwa Lee,et al. Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome , 2009, Cell.
[29] Alexander D. MacKerell,et al. Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay. , 2008, Journal of medicinal chemistry.
[30] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[31] M. Dawson,et al. Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containin , 2008, Journal of medicinal chemistry.
[32] W. Guida,et al. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. , 2008, Journal of medicinal chemistry.
[33] A. Dixit,et al. 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. , 2008, Journal of medicinal chemistry.
[34] S. Kondo,et al. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors , 2008, Oncogene.
[35] Jörg Rademann,et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking , 2008, Proceedings of the National Academy of Sciences.
[36] J. Salles,et al. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. , 2008, Cellular signalling.
[37] Andy Hudmon,et al. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases , 2007, Proceedings of the National Academy of Sciences.
[38] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[39] G. Feng,et al. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. , 2007, Blood.
[40] N. Tonks,et al. Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.
[41] W. Guida,et al. Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor , 2006, Molecular Pharmacology.
[42] Wladek Minor,et al. HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.
[43] Herbert Waldmann,et al. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[44] A. Nebreda,et al. Protein kinases and phosphatases as therapeutic targets in cancer , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[45] M. Loh,et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. , 2005, Blood.
[46] Bruce D Gelb,et al. Noonan syndrome and related disorders: genetics and pathogenesis. , 2005, Annual review of genomics and human genetics.
[47] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[48] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[49] John D. Minna,et al. Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.
[50] M. Loh,et al. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group , 2004, Leukemia.
[51] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[52] B. Gelb,et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.
[53] Giovanni Parmigiani,et al. Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.
[54] M. Loh,et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.
[55] R. Jove,et al. Roles of Gab1 and SHP2 in Paxillin Tyrosine Dephosphorylation and Src Activation in Response to Epidermal Growth Factor* , 2004, Journal of Biological Chemistry.
[56] B. Neel,et al. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.
[57] J. Licht,et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.
[58] Zhon-Yin Zhang,et al. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. , 2002, Annual review of pharmacology and toxicology.
[59] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[60] Z. Zhang,et al. Protein tyrosine phosphatases: prospects for therapeutics. , 2001, Current opinion in chemical biology.
[61] Y. Ma,et al. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.
[62] M F Sanner,et al. Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.
[63] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[64] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[65] D S Lawrence,et al. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[66] A. Vagin,et al. MOLREP: an Automated Program for Molecular Replacement , 1997 .
[67] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[68] Shigeo Ohno,et al. Protein Kinase C δ Activates the MEK-ERK Pathway in a Manner Independent of Ras and Dependent on Raf* , 1996, The Journal of Biological Chemistry.
[69] A. Saltiel,et al. Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[70] S. Stabel,et al. Signalling from TPA to MAP kinase requires protein kinase C, raf and MEK: reconstitution of the signalling pathway in vitro. , 1994, Oncogene.
[71] A. Brunger. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .
[72] A. Brünger. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures , 1992, Nature.